SCHEMBL5116673

SCHEMBL5116673

Cc1cccc(-c2nc3ccc(Cl)nn3c2-c2ccnc(F)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.46
MAPK13 O15264 10/20 0.46
MAPK12 P53778 10/20 0.46
MAPK11 Q15759 10/20 0.46
AKT1 P31749 1/20 0.41
AKT2 P31751 1/20 0.41
RIPK3 Q9Y572 3/20 0.39
SYK P43405 1/20 0.37
CSNK1D P48730 1/20 0.37
CSNK1E P49674 1/20 0.37
DYRK3 O43781 1/20 0.37
CCNT1 O60563 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CDK9 P50750 1/20 0.37
CDK5 Q00535 1/20 0.37
DYRK1A Q13627 1/20 0.37
CDK5R1 Q15078 1/20 0.37
DYRK2 Q92630 1/20 0.37
DYRK1B Q9Y463 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118834 0.88 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5127049 0.84 MAPK14 (0.42) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5120095 0.83 MAPK14 (0.63) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5125059 0.82 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5126526 0.82 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5120116 0.81 MAPK13 (0.50) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5118524 0.81 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5119031 0.80 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11
SCHEMBL3104269 0.79 AKT1 (0.52) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5126524 0.76 DYRK3 (0.48) MAPK14MAPK13MAPK12MAPK11AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof MAPK13, MMP13, MAPK3 MAPK14 5/4885MAPK13 1/4885MAPK12 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.